Symbol="IVVD"
AssetType="Common Stock"
Name="Invivyd Inc."
Description="Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts."
CIK="1832038"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="303 WYMAN STREET, SUITE 300, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="179550000"
EBITDA="-165468000"
PERatio="None"
PEGRatio="None"
BookValue="2.565"
DividendPerShare="0"
DividendYield="0"
EPS="-1.68"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.259"
ReturnOnEquityTTM="-0.503"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.68"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.499"
EVToRevenue="-"
EVToEBITDA="0.821"
Beta="-0.0474"
num_52WeekHigh="4.9"
num_52WeekLow="0.98"
num_50DayMovingAverage="1.342"
num_200DayMovingAverage="1.748"
SharesOutstanding="109482000"
DividendDate="None"
ExDividendDate="None"
symbol="IVVD"
open="1.60"
high="1.68"
low="1.57"
price="1.66"
volume="101168.00"
latest_trading_day="2023-08-16"
previous_close="1.64"
change="0.02"
change_percent="1.2195%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="87"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="13"
Volume_recent_avg="330617"
Change_recent_avg="0.01"
Delta_recent_avg="0.13"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.28"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="13"
Aroon_momentum_negative="87"
image_negative_thumbnail_id_1="1108"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0141.jpeg"
image_negative_thumbnail_id_2="136"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0040.jpeg"
image_neutral_thumbnail_id_1="582"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_neutral_thumbnail_id_2="540"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_positive_thumbnail_id_1="661"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0047.jpeg"
image_positive_thumbnail_id_2="659"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0049.jpeg"
image_professor_thumbnail_id_1="1173"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
